Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients. A randomized crossover study

Journal of Diabetes and its Complications

Volumn 20, Issue 3, 2006, Pages 179-183

  Shimabukuro, Michio ^a   Higa, Namio ^a   Takasu, Nobuyuki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

8iPGF2 ; Endothelial function; Sulphonylurea

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANTIOXIDANT; GLIBENCLAMIDE; GLICLAZIDE; SULFONYLUREA;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD FLOWMETRY; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPEREMIA; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

AGED; ANTIOXIDANTS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BODY MASS INDEX; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DINOPROST; DOUBLE-BLIND METHOD; FEMALE; FOREARM; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; VASCULAR RESISTANCE;

EID: 33646071844     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2005.06.012     Document Type: Article

References (21)

1. Antoniades C., Tousoulis D., Tauntas C., Tentolouris C., Toutouza M., Vasiliadou C., et al. Vascular endothelium and inflammatory process, in patients with combined type 2 diabetes mellitus and coronary atherosclerosis: The effect of vitamin C. Diabetic Medicine 21 (2004) 552-558
2. Ashcroft F.M., and Gribble FM. Tissue specific effects of sulphonylureas: Lessons from studies of cloned KATP channels. Journal of Diabetes and its Complications 14 (2000) 192-196
3. Calles-Escandon J., and Cipolla M. Diabetes and endothelial dysfunction. Endocrine Reviews 2 (2001) 36-52
4. 2α and platelet activation in diabetes mellitus; effect of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
5. Dhindsa P., Davis K.R., and Donnelly R. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with type 2 diabetes: A double-blind, crossover study. British Journal of Clinical Pharmacology 55 (2003) 616-619
6. Fava D., Cassone-Faldetta M., Laurenti O., De Luca O., Ghiselli A., and De Mattia G. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes. Diabetic Medicine 19 (2002) 752-757
7. Friedewald W.T., Levy R.I., and Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry 18 (1972) 499-502
8. Gribble F.M., Tucker S.J., Seino S., and Ashcroft FM. Tissue specificity of sulphonylureas: Studies on cloned cardiac and b-cell KATP channels. Diabetes 47 (1998) 1412-1418
9. Jennings P.E., and Belch J.J.F. Free radical scavenging activity of sulfonylureas: A clinical assessment of the effect of gliclazide. Metabolism 49 (2000) 23-26
10. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., and Roberts II L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 9383-9387
11. O'Brien R.C., Luo M., Balazs N., and Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. Journal of Diabetes and its Complications 14 (2000) 201-206
12. 2α as a risk marker in patients with coronary heart disease. A matched case-control study. Circulation 109 (2004) 843-848
13. Scott N.A., Jennings P.E., Brown J., and Belch J.J.F. Gliclazide: A general free radical scavenger. European Journal of Pharmacology 208 (1991) 175-177
14. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. Journal of Clinical Endocrinology and Metabolism 88 (2003) 3236-3240
15. Shimabukuro M., Higa N., Takasu N., Tagawa T., and Ueda S. A single dose of nateglinide improves postchallenge endothelial dysfunction in type 2 diabetic patients. Diabetic Medicine 21 (2004) 983-986
16. Shimabukuro M., Nagamine F., Murakami K., Oshiro K., and Mimura G. Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. General Pharmacology 25 (1994) 697-704
17. Shinzato T., Shimabukuro M., Higa S., Nagamine F., Murakami K., and Takasu N. Effect of gliclazide on the functional response to calcium in diabetic rat heart. General Pharmacology 27 (1996) 471-475
18. Skrha J., Hodinar A., Kvasnicka J., and Hilgertova J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabetic Medicine 13 (1996) 800-805
19. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radical Biology & Medicine 16 (1994) 383-391
20. Wang Z., Ciabattoni G., Creminon C., Lawson J., Fitzgerald G.A., Patorono C., et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. Journal of Pharmacology and Experimental Therapeutics 275 (1995) 94-100
21. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology 27 (1996) 567-574